Androgen Receptor

The FDA granted fast track designation to Lipocine’s LPCN 1148, an oral androgen receptor agonist containing testosterone dodecanoate, for the treatment of sarcopenia in patients with decompensated cirrhosis, according to the manufacturer.

SAN FRANCISCO — Bavdegalutamide demonstrated clinical activity among heavily pretreated men with metastatic castration-resistant prostate cancer who received novel hormonal agents, according to study results presented at ASCO Genitourinary Cancers Symposium.

A subset of patients with breast cancer may benefit from treatment with enobosarm, a novel oral selective androgen receptor agonist, according to research presented at ASCO 2021.